Phase 1 Parkinson's Disease Trial, Recruiting NCT06683378 Sponsor: Craig van Horne, MD, PhD Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 1 Parkinson's Disease Trial, Recruiting

NCT06683378
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are already scheduled to undergo deep brain stimulation (DBS), a type of brain surgery used to treat movement disorders
  • People who have been diagnosed with Parkinson's disease (PD) according to recognised medical guidelines (either a confirmed or highly likely diagnosis)
  • People aged between 45 and 75 years old (inclusive)
  • People who are healthy enough to safely go through the surgical procedure
  • People who are able to complete all of the planned tests and assessments involved in the trial
  • People who have a suitable sural nerve available (a nerve located in the lower leg) (confirm with trial site)

Who may not be able to join:

  • People who have a health condition that would make them unsuitable for deep brain stimulation surgery
  • People who have been diagnosed with dementia
  • People who have previously had brain surgery or surgery related to Parkinson's disease
  • People who are unable to have an MRI scan
  • People whose brain anatomy does not allow a clear surgical path to the specific brain regions targeted in this trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Craig G van Horne, MD, PhD, University of Kentucky

Phone: 8593231908

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Craig van Horne, MD, PhD
Registry
ClinicalTrials.gov
Start date
21 July 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Successful deployment of bilateral peripheral nerve tissue (PNT) into the brain; Number of participants completing 12 month study visit; Study-related adverse events as assessed by MedDRA v27; Study-related serious adverse events as assessed by MedDRA v.27

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov